Cell therapies for joint repair/regeneration
The first meeting of FDA's Cellular, Tissue & Gene Therapies Advisory Committee on March 3-4 will address cellular therapies for joint surface repair and regeneration. The panel is the former Biological Response Modifiers Advisory Committee, renamed in October by FDA to reflect more accurately its purview. The committee will also hear updates on research programs in the Center for Biologics Evaluation & Research the afternoon of March 3 and on FDA's Critical Path Initiative the morning of March 4. The meeting will be held at the Quality Suites in Rockville, Md. at 8 a.m. [Editor's Note: To 1watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.]...
You may also be interested in...
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The International Medical Device Regulators Forum, perhaps most notorious for its efforts to standardize audit processes between nations with its Medical Device Single Audit Program, is also focusing on harmonizing device reviews and adverse event codes.
Dr Reddy’s Laboratories has become the third Revlimid ANDA sponsor to settle patent litigation action with Bristol Myers Squibb’s Celgene. However, the Indian company will join Alvogen in not being able to launch before first settler Natco, which has partnered with Teva’s Watson.